Management of Hypertensive Emergencies in the ICU

Definitions and Clinical Distinction

• Hypertensive emergency is defined as a systolic/diastolic blood pressure > 180/120 mmHg with acute target‑organ damage (e.g., encephalopathy, stroke, myocardial infarction, pulmonary edema, aortic dissection, renal failure, eclampsia) and mandates ICU admission for continuous monitoring and parenteral antihypertensive therapy【1】.
• Hypertensive urgency is severe blood pressure elevation without acute organ damage; these patients do not require ICU admission or intravenous agents and can be managed with oral therapy【1】.

Initial Management and Setting

• All patients with hypertensive emergencies should be admitted to an intensive care unit, receive continuous arterial blood‑pressure monitoring, and be treated with titratable intravenous agents to allow precise control【1】.

Blood‑Pressure Reduction Targets

• First hour – reduce systolic BP by ≤ 25 % of the presenting value【1】.
• Next 2–6 hours – if the patient remains stable, lower BP to ≤ 160/100 mmHg【1】.
• 24–48 hours – cautiously normalize BP to a target of 130–140 mmHg systolic【2】.
• Avoid a rapid fall in mean arterial pressure > 50 % because it is linked to ischemic stroke and increased mortality, especially in patients with chronic hypertension and impaired autoregulation【3】.

Condition‑Specific BP Goals

First‑Line Intravenous Antihypertensive Agents

• Labetalol (combined α/β‑blocker) – preferred for malignant hypertension, hypertensive encephalopathy, and both ischemic and hemorrhagic stroke; dose 0.3–1 mg/kg IV bolus (max 20 mg) q10 min or 0.4–1 mg/kg/h infusion (max 3 mg/kg/h); onset 5–10 min, duration 3–6 h【1】. Avoid in acute heart failure, severe bradycardia, or heart block【1】.
• Nicardipine (dihydropyridine calcium‑channel blocker) – first‑line for most hypertensive emergencies except acute heart failure; start 5 mg/h, increase by 2.5 mg/h every 5 min up to 15 mg/h; onset 5–10 min, duration 15–30 min (may exceed 4 h)【1】. Evidence shows it achieves short‑term BP targets more effectively than labetalol【2】.

Alternative or Adjunctive Agents for Specific Situations

• Sodium nitroprusside (with loop diuretic) – indicated for acute cardiogenic pulmonary edema; start 0.3–0.5 µg/kg/min, titrate up to 10 µg/kg/min【1】. Monitor for cyanide toxicity; administer thiosulfate when infusion ≥ 4–10 µg/kg/min or duration > 30 min【1】.
• Esmolol + nitroprusside/nitroglycerin – first‑line for acute aortic dissection; β‑blockade reduces shear stress before vasodilation【3】.
• Nitroglycerin – preferred for acute coronary syndrome; start 5 µg/min, increase by 5 µg/min every 3–5 min to max 20 µg/min【1】.

Agents to Avoid

• Short‑acting nifedipine – contraindicated because of unpredictable, precipitous BP drops that can precipitate cardiovascular complications【3】.
• Routine use of sodium nitroprusside as first‑line – should be reserved for specific indications (e.g., pulmonary edema, aortic dissection) due to significant toxicity risk【3】.

Management of Hypertensive Urgency (No Organ Damage)

• No ICU admission; treat with oral antihypertensives (e.g., captopril, oral labetalol, extended‑release nifedipine)【1】.
• Observe for ≥ 2 hours to assess efficacy and safety【3】.
• Arrange outpatient follow‑up within days to weeks【4】.
• Avoid rapid BP lowering to prevent cardiovascular complications【3】.

Monitoring Requirements for Emergencies

• Continuous invasive BP monitoring in the ICU.
• Ongoing assessment for development or progression of target‑organ damage.
• Use of titratable IV agents to permit precise BP adjustments.

Common Pitfalls and Safety Considerations

• Over‑aggressive BP reduction can cause ischemic injury in organs with impaired autoregulation【3】.
• Treating urgencies as emergencies leads to unnecessary ICU stays and IV therapy【1】.
• Inappropriate drug selection (e.g., short‑acting nifedipine, indiscriminate nitroprusside) should be avoided【3】.
• Uniform BP targets are inappropriate; goals must be individualized based on the specific organ injury present【3】.
• Chronic hypertension patients tolerate higher pressures; rapid normalization increases risk of adverse events【1】.

Management of Hypertensive Emergencies in Critically Ill ICU Patients

1. Definition and Clinical Decision‑Making

2. Blood‑Pressure Reduction Targets

2.1 Standard Approach (no specific compelling condition)

2.2 Condition‑Specific First‑Hour Targets

3. First‑Line Intravenous Antihypertensive Agents

3.1 Labetalol (combined α/β‑blocker)

3.2 Nicardipine (dihydropyridine calcium‑channel blocker)

3.3 Condition‑Specific Agents

4. Agents to Avoid

5. Common Pitfalls and Safety Considerations

6. Monitoring Requirements for Hypertensive Emergencies

Blood Pressure Management in Acute Intracerebral Hemorrhage

Target Blood Pressure Goals

• In patients with acute intracerebral hemorrhage, systolic blood pressure should be kept below 140 mmHg to minimize the risk of re‑bleeding. 10

Risks of Abrupt Discontinuation

• Abrupt cessation of IV nicardipine without an overlapping oral antihypertensive can cause rapid rebound hypertension, which significantly raises the likelihood of hematoma expansion and worsens clinical outcomes in acute intracerebral hemorrhage. 10

Management of Severe Hypertension and Hypertensive Emergencies

Immediate Assessment for Hypertensive-Mediated Organ Damage

• Perform a focused neurologic examination to detect altered mental status, seizures, focal deficits, severe headache, or visual changes that may indicate encephalopathy, stroke, or intracranial hemorrhage. 11
• Conduct a cardiovascular assessment for chest pain, dyspnea/pulmonary edema, or signs of aortic dissection (tearing chest/back pain, pulse differentials). 11
• Perform fundoscopic examination to look for papilledema, retinal hemorrhages, or cotton‑wool spots suggestive of malignant hypertension. 11
• Obtain laboratory studies including serum creatinine, cardiac troponin, urinalysis, and complete blood count to identify acute kidney injury, myocardial injury, proteinuria/hematuria, or thrombotic microangiopathy. 11
• Review medication history to differentiate non‑adherence from new‑onset severe hypertension. 11

Hypertensive Emergency (Acute Target‑Organ Damage)

ICU Admission and Monitoring

• Admit the patient to an intensive‑care unit immediately for continuous invasive arterial blood‑pressure monitoring. [12][13]
• Use titratable intravenous antihypertensive agents to achieve precise blood‑pressure control. [12][13]

Blood‑Pressure Reduction Targets (Standard Approach)

• First hour: Reduce systolic blood pressure by no more than 25 % of the presenting value. [12][11]14
• Next 2–6 hours (if stable): Lower blood pressure to < 160/100 mmHg. [12][11]14
• 24–48 hours: Cautiously normalize systolic pressure to 130–140 mmHg. [12][13]

Condition‑Specific Targets

Severe Hypertension Without Acute Target‑Organ Damage (Hypertensive Urgency)

• Do not admit to the ICU and avoid intravenous antihypertensives; such aggressive management is linked to higher rates of acute kidney injury, stroke, and myocardial infarction. [12][13]

Outpatient Management Strategy

• Re‑initiate or intensify oral antihypertensive therapy (e.g., captopril, oral labetalol, extended‑release nifedipine). [12][13]
• Reduce blood pressure gradually over 24–48 hours to minimize risk of hypoperfusion. [11][14]
• Observe the patient for at least 2 hours after medication adjustment to assess efficacy and safety.
• Arrange outpatient follow‑up within days to weeks.

Risks of Over‑Aggressive Lowering

• Aggressive acute lowering in asymptomatic patients increases adverse events (e.g., AKI, stroke, MI). 12

Clinical Pitfalls and Safety Considerations

• Over‑aggressive reduction can cause vital‑organ hypoperfusion in patients with chronic hypertension and impaired autoregulation. [12][13]
• Uniform blood‑pressure targets are inappropriate; goals must be tailored to the specific organ injury present.
• Routine use of sodium nitroprusside as a first‑line agent should be avoided except for specific indications (pulmonary edema, aortic dissection) due to cyanide toxicity risk.
• In hospitalized patients with severe hypertension without acute target‑organ damage, intermittent IV or oral antihypertensives for rapid reduction are not recommended (Class III: Harm). 12

Hypertensive Emergency with Malignant Hypertensive Retinopathy and Papilledema

Definition and Immediate Management

• All patients presenting with malignant hypertension and papilledema should be admitted to an intensive‑care unit and monitored with continuous invasive arterial blood‑pressure measurement to allow precise titration of intravenous antihypertensive agents. 15
• This clinical picture represents a true hypertensive emergency, characterized by acute hypertension‑mediated organ damage to the retina and optic nerve. [15][16]

Blood‑Pressure Reduction Targets

• During the first several hours of treatment, the mean arterial pressure (MAP) should be lowered by 20 %–25 % from the presenting value. 15
• MAP reduction greater than 50 % is associated with ischemic stroke and death, particularly in patients with chronic hypertension and impaired autoregulation; therefore, such a rapid fall must be avoided. 15

First‑Line Pharmacologic Treatment

• Intravenous labetalol is the preferred first‑line agent for malignant hypertension with retinopathy because it provides a smooth, controlled blood‑pressure decline through combined α‑ and β‑blockade. 15
• Recommended labetalol dosing (based on adult weight):
  
  • Bolus: 0.3–1 mg kg⁻¹ IV (maximum 20 mg) every 10 minutes, or
  • Continuous infusion: 0.4–1 mg kg⁻¹ h⁻¹ (maximum 3 mg kg⁻¹ h⁻¹).
  • These dosing regimens are supported by clinical guidance. 17

Alternative Pharmacologic Options (when labetalol is contraindicated or ineffective)

• Nicardipine – start at 5 mg h⁻¹ and increase by 2.5 mg h⁻¹ every 5 minutes up to a maximum of 15 mg h⁻¹. 15
• Sodium nitroprusside – initiate at 0.3–0.5 µg kg⁻¹ min⁻¹ and titrate up to 10 µg kg⁻¹ min⁻¹; use cautiously because of cyanide‑toxicity risk. 15
• Urapidil – may be used where available as an alternative intravenous agent. 15

Contraindicated Medications

• Short‑acting nifedipine is absolutely contraindicated because it can cause unpredictable, precipitous blood‑pressure drops that increase the risk of stroke and other cardiovascular complications. [15][17]

Assessment of Multiorgan Involvement

• Malignant hypertension frequently involves multiple organ systems; therefore, a systematic evaluation is required:
  
  • Neurologic: assess for altered mental status, seizures, focal deficits, or severe headache suggestive of hypertensive encephalopathy. 17
  • Cardiac: inquire about chest pain, dyspnea, or signs of pulmonary edema. [15][16]
  • Renal: obtain serum creatinine and urinalysis to detect acute kidney injury, proteinuria, or hematuria. [15][16]
  • Hematologic: perform a complete blood count to screen for thrombotic microangiopathy (schistocytes, thrombocytopenia). 15

Ophthalmic Findings Relevant to Diagnosis

• Presence of cotton‑wool spots indicates nerve‑fiber‑layer infarcts and supports the diagnosis of hypertensive retinopathy. 17

Screening for Secondary Causes

• Consider secondary etiologies such as pheochromocytoma, especially in patients without a prior history of hypertension; appropriate biochemical testing (plasma and urinary metanephrines) should be performed when clinically indicated. 15

Transition to Oral Antihypertensive Therapy

• After 24–48 hours of stable intravenous control without progression of organ damage, initiate oral antihypertensive agents with overlap of the IV infusion to prevent rebound hypertension. Common oral choices include ACE inhibitors, calcium‑channel blockers, or beta‑blockers, selected according to comorbid conditions. 17

Key Safety Principles

• Do not treat malignant hypertension with papilledema as a hypertensive urgency; oral agents in an outpatient setting are insufficient and increase morbidity. 16
• Avoid overly aggressive blood‑pressure normalization in patients with chronic hypertension, as this can cause vital‑organ hypoperfusion due to impaired autoregulation; aim for controlled, gradual reduction instead. 15

Management of Hypertensive Emergency in Elderly Patients

1. Immediate Clinical Assessment

• Vomiting in the setting of severe hypertension may indicate hypertensive encephalopathy or raised intracranial pressure (European Society of Cardiology guideline) 18

2. Blood‑Pressure Reduction Targets

• First‑hour goal: Reduce systolic blood pressure by ≤ 25 % of the presenting value (e.g., from 240 mmHg to ≈ 180 mmHg) (ESC guideline) 18, 19
• Mean arterial pressure should not be lowered by more than 50 % to avoid ischemic stroke and death, particularly in elderly patients with chronic hypertension and impaired autoregulation (ESC guideline) 18
• 2–6‑hour goal (if clinically stable): Lower blood pressure to ≤ 160/100 mmHg (ESC guideline) 18, 19
• 24–48‑hour goal: Cautiously normalize systolic pressure to 130–140 mmHg (ESC guideline) 18

3. First‑Line Intravenous Antihypertensive Therapy

• Intravenous labetalol is the preferred first‑line agent for malignant hypertension and hypertensive encephalopathy (ESC guideline) 18, 19
  
  • Bolus dose: 0.3–1 mg/kg IV (maximum 20 mg) every 10 minutes.
  • Continuous infusion: 0.4–1 mg/kg/h (maximum 3 mg/kg/h).
  • Onset of action: 5–10 minutes; duration: 3–6 hours (ESC guideline) 18
• Contraindications to labetalol include acute heart failure, severe bradycardia, or heart block (ESC guideline) 18

Alternative Agent

• Intravenous nicardipine should be used when labetalol is contraindicated or ineffective (ESC guideline) 18, 19
  
  • Starting dose: 5 mg/h, titrated upward by 2.5 mg/h every 5 minutes to a maximum of 15 mg/h.
  • Onset: 5–10 minutes; duration: 15–30 minutes (ESC guideline) 18

4. Medications to Avoid

• Short‑acting nifedipine is contraindicated because it can cause unpredictable, precipitous blood‑pressure drops that precipitate cardiovascular complications (ESC guideline) 18, 19

5. Monitoring Requirements

• Continuous invasive arterial blood‑pressure monitoring in an intensive‑care setting is required to allow precise titration of intravenous agents (ESC guideline) 18, 19
• Use of titratable intravenous agents is recommended to permit rapid and controlled blood‑pressure adjustments (ESC guideline) 18, 19

6. Management of Associated Vomiting

• Vomiting is expected to improve as blood pressure is controlled when it is secondary to hypertensive encephalopathy (ESC guideline) 18

Guideline Recommendations for Managing Hypertensive Urgency and the Role of Clonidine

1. Guideline Stance on Aggressive Blood‑Pressure Lowering

• The 2017 ACC/AHA and 2025 AHA/ACC guidelines state that adults with severe hypertension (>180/120 mm Hg) without acute target‑organ damage should not receive aggressive acute blood‑pressure lowering with either intravenous or oral agents, because such an approach increases the risk of acute kidney injury, stroke, and myocardial infarction. Class III: Harm recommendation. 20
• The 2025 AHA/ACC guidelines give a Class III: Harm recommendation against the intermittent use of additional IV or oral antihypertensive medications to acutely reduce blood pressure in hospitalized patients with asymptomatic severe hypertension. 20
• Blood pressure in these patients should be reduced gradually over 24–48 hours, rather than acutely, to minimise the risk of hypoperfusion in chronically hypertensive individuals with impaired autoregulation. 20

2. Recommended Outpatient Management of Hypertensive Urgency

• Hypertensive urgency (severe hypertension without organ damage) should be managed by re‑starting or intensifying the patient’s existing oral antihypertensive regimen (e.g., ACE inhibitor, ARB, calcium‑channel blocker, thiazide diuretic) in the outpatient setting, instead of using rapid‑acting agents such as clonidine. 20

3. Specific Indications for Clonidine in Hypertensive Emergencies

• Clonidine is indicated only in hypertensive emergencies caused by catecholamine excess, including:

  • Pheochromocytoma crisis
  • Cocaine toxicity
  • Amphetamine overdose
  • Clonidine‑withdrawal syndrome (paradoxically treated with phentolamine)
  • MAO‑inhibitor interactions

• In these emergencies, patients require ICU admission with continuous invasive arterial blood‑pressure monitoring and parenteral therapy to ensure safe and controlled BP reduction. [21][22][25][20]

4. Safety Considerations and Common Pitfalls

• Do not treat asymptomatic severe hypertension as an emergency; doing so leads to unnecessary ICU admissions, intravenous therapy, and worse clinical outcomes. 20

All bullet points are derived from cited evidence and reflect the current recommendations of the American College of Cardiology/American Heart Association and peer‑reviewed literature.

Management of Severe Hypertension (SBP ≈ 200 mmHg) in the Clinic

1. Initial Clinical Assessment

• Neurologic screening for seizure activity or somnolence should be performed to identify possible hypertensive encephalopathy or stroke. 26
• Detection of pulse pressure differentials between extremities is recommended as a bedside clue for aortic dissection. 26
• Inquiry about recent use of cocaine, methamphetamine, or other sympathomimetics is essential because these agents can precipitate severe hypertension. 26

2. Determining Hypertensive Emergency vs. Urgency

• Patients without acute target‑organ damage do not require ICU admission or intravenous antihypertensive therapy; outpatient management is appropriate. [27][26]

3. Hypertensive Emergency (Acute Target‑Organ Damage Present)

3.1. Admission and Monitoring

• Immediate ICU admission with continuous invasive arterial blood‑pressure monitoring is advised. [27][26]
• Titrable intravenous antihypertensive agents should be used to achieve controlled BP reduction. [27][26]

3.2. Blood‑Pressure Reduction Targets

3.3. First‑Line Intravenous Medications

• Nicardipine is the preferred agent for most hypertensive emergencies (except acute heart failure) and has demonstrated superior achievement of short‑term BP targets compared with labetalol. Start 5 mg/h, titrate by 2.5 mg/h every 5 min to a maximum of 15 mg/h. 27
• Labetalol is preferred for malignant hypertension, hypertensive encephalopathy, and stroke (bolus 0.3–1 mg/kg IV, max 20 mg; infusion 0.4–1 mg/kg/h, max 3 mg/kg/h) but is contraindicated in acute heart failure, severe bradycardia, or high‑grade heart block. 27

3.4. Medications to Avoid

• Short‑acting nifedipine is absolutely contraindicated because it can cause unpredictable, precipitous BP drops and increase cardiovascular complications. 26

4. Hypertensive Urgency (No Acute Target‑Organ Damage)

4.1. Management Principles

• Do not admit to ICU, do not use IV antihypertensives, and avoid aggressive acute BP lowering; such practices are linked to higher rates of AKI, stroke, and MI. 27

4.2. Outpatient Oral Therapy

• Re‑initiate or intensify oral antihypertensive regimen (ACE‑I/ARB, calcium‑channel blocker, thiazide diuretic). 26
• Gradual BP reduction over 24–48 hours is recommended rather than rapid drops. 26
• Combination therapy is often required; consider adding a second oral agent when monotherapy is insufficient. 28

4.3. Agents to Exclude in Urgency

• Clonidine should be reserved for catecholamine‑excess emergencies (e.g., pheochromocytoma, cocaine toxicity) and not used routinely for hypertensive urgency. 26
• Short‑acting nifedipine (as above) and routine clonidine use are discouraged. 26

5. Guideline Recommendations & Evidence Strength

• 2025 AHA/ACC guideline assigns a Class III (Harm) recommendation (strong evidence) against intermittent IV or oral antihypertensives for acute BP reduction in hospitalized patients with severe hypertension without acute target‑organ damage. 27
• European Society of Cardiology (ESC) 2024 guidance emphasizes careful BP reduction targets and avoidance of precipitous agents (nicardipine preferred, short‑acting nifedipine contraindicated). 26

All patient identifiers have been generalized; numeric values are presented as illustrative targets.

Evidence‑Based Management of Hypertensive Emergencies

Initial Assessment and ICU Admission

• All patients presenting with a hypertensive emergency should be admitted immediately to an intensive‑care unit and monitored with continuous invasive arterial blood‑pressure measurement to enable precise titration of intravenous agents. 29

Blood‑Pressure Reduction Targets

General Time‑Based Goals

• First hour: lower systolic blood pressure (SBP) by ≤ 25 % of the presenting value (e.g., from 220 mmHg to ≤ 165 mmHg). 29
• Hours 2–6 (if clinically stable): achieve a BP ≤ 160/100 mmHg. 29
• Hours 24–48: cautiously normalize SBP to 130–140 mmHg. 29

Condition‑Specific First‑Hour Targets

All targets are derived from the European Heart Journal consensus on hypertensive emergencies. 29

First‑Line Intravenous Antihypertensive Agents

Nicardipine (Preferred for Most Emergencies)

• Dose: start at 5 mg/h, increase by 2.5 mg/h every 5 min up to a maximum of 15 mg/h. 29
• Pharmacology: onset of action 5–10 min; effective duration 15–30 min (can exceed 4 h). 29
• Adverse effects: headache and reflex tachycardia. 29

Labetalol (Alternative / Preferred for Specific Conditions)

• Indications: malignant hypertension, hypertensive encephalopathy, and both ischemic and hemorrhagic stroke. 29
• Dose: 0.3–1 mg/kg IV bolus (max 20 mg) every 10 min or continuous infusion 0.4–1 mg/kg/h (max 3 mg/kg/h). 29
• Pharmacology: onset 5–10 min; duration 3–6 h. 29
• Contra‑indications: acute heart failure, severe bradycardia, second‑ or third‑degree AV block, and asthma. 29

Condition‑Specific Agent Selection

• Aortic dissection: initiate esmolol (β‑blocker) to achieve HR < 60 bpm, then add sodium nitroprusside or nitroglycerin for vasodilation. (β‑blockade must precede vasodilation). 29

• Acute cardiogenic pulmonary edema: Sodium nitroprusside 0.3–0.5 µg/kg/min, titrated ≤ 10 µg/kg/min, combined with a loop diuretic, is the drug of choice. 29

  • Alternative: nitroglycerin may be used. 29

• Acute coronary syndrome: Nitroglycerin is preferred; start at 5 µg/min, increase by 5 µg/min every 3–5 min to a maximum of 20 µg/min. Additional β‑blockade may be added if tachycardia is present. 29

  • Avoid: sodium nitroprusside, because it can reduce regional coronary flow and increase myocardial injury. 29

• Acute intracerebral hemorrhage: Labetalol is the drug of choice for rapid BP reduction; nicardipine and sodium nitroprusside are acceptable alternatives. 29

Medications to Absolutely Avoid

• Short‑acting nifedipine is contraindicated in all hypertensive emergencies due to the risk of unpredictable, precipitous BP drops that can precipitate stroke and other cardiovascular complications. 29

All recommendations are based on the evidence summarized in the European Heart Journal (2019) and reflect the strongest available data for each intervention. 29

Management of Hypertensive Urgency (AHA/ACC 2025 Guidelines)

Definition and Risk

• Hypertensive urgency is defined as a severe blood pressure reading > 180/120 mmHg without acute target‑organ damage; it should be treated with oral antihypertensives in the outpatient setting, never with intravenous agents or ICU admission, because aggressive acute lowering raises the risk of acute kidney injury, stroke, and myocardial infarction. Class III (Harm) 30

Diagnostic Distinction

• Before any therapy, clinicians must determine whether acute target‑organ damage is present (e.g., neurologic deficits, chest pain, pulmonary edema, renal dysfunction) to separate hypertensive urgency from hypertensive emergency. Class I (Strong) 30

Recommendations Against Aggressive Management (Class III: Harm)

• ICU admission is not indicated for hypertensive urgency. 30
• Intravenous antihypertensive agents (nicardipine, labetalol, nitroprusside) should not be used. 30
• Short‑acting nifedipine is contraindicated because of unpredictable precipitous drops. 30
• Clonidine is reserved only for catecholamine‑excess emergencies (e.g., pheochromocytoma, cocaine toxicity) and is not recommended for routine hypertensive urgency. 30

Outpatient Oral Therapy (Class I: Strong)

• Re‑initiate or intensify the patient’s existing oral antihypertensive regimen. 30
• First‑line oral agents include an ACE inhibitor, an ARB, a long‑acting calcium‑channel blocker, or a thiazide diuretic. 30
• Combination therapy may be required when monotherapy does not achieve target control. 30
• Blood pressure should be reduced gradually over 24–48 hours, avoiding rapid drops. 30

Monitoring and Follow‑up (Class I: Strong)

• After medication adjustment, observe the patient for at least 2 hours to assess efficacy and safety. 30
• Arrange outpatient follow‑up within days to weeks to ensure sustained control. 30

Pathophysiologic Rationale (Class I: Strong)

• Chronic hypertension shifts cerebral, renal, and coronary autoregulation curves rightward; rapid BP normalization can cause hypoperfusion of these vital organs. 30

Outcomes of Mismanagement (Class I: Strong)

• Treating asymptomatic severe hypertension as an emergency occurs in roughly one‑third of inpatient cases and is associated with worse outcomes, including higher rates of AKI, stroke, and myocardial infarction. 30

Red Flags Signaling Progression to Hypertensive Emergency (Class I: Strong)

• Development of new neurologic symptoms (confusion, seizure, focal deficit).
• Onset of chest pain or electrocardiographic changes.
• Rising serum creatinine or oliguria.
• Presence of papilledema on fundoscopic exam.
• Any of these findings mandate re‑classification to hypertensive emergency. 30

Emergency Management Protocol (Applicable When Red Flags Appear) (Class I: Strong)

• Admit the patient to the ICU, initiate continuous invasive arterial blood‑pressure monitoring, and start titratable intravenous agents (nicardipine or labetalol) to lower systolic BP by ≤ 25 % within the first hour. 30